SEC FIlings Archives - Page 15 of 19

04 Apr

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

04 Apr

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

21 Mar

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

21 Mar

SEC FIlings

Current report

November 17, 2022
Posted by Jitendra

18 Mar

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

24 Feb

SEC FIlings

Annual report for fiscal year ending Dec 31, 2021

November 17, 2022
Posted by Jitendra

18 Feb

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

18 Feb

SEC FIlings

Current report

November 17, 2022
Posted by Jitendra

14 Feb

SEC FIlings

Statement of acquisition of beneficial ownership by individuals – Amendment

November 17, 2022
Posted by Jitendra

11 Feb

SEC FIlings

Statement of acquisition of beneficial ownership by individuals

November 17, 2022
Posted by Jitendra

SEC FIlings

Prospectuses and communications, business combinations

Prospectuses and communications, business combinations

Prospectuses and communications, business combinations

Current report

Prospectuses and communications, business combinations

Annual report for fiscal year ending Dec 31, 2021

Prospectuses and communications, business combinations

Current report

Statement of acquisition of beneficial ownership by individuals – Amendment

Statement of acquisition of beneficial ownership by individuals

test according

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists